sofidexFor patientsAre you a clinician? Clinical site
Ask Sofi
Listen
Patient SupportEmergencies & Reporting
Log inSign up

Meds & supplements  ›  Ocrelizumab

Medicine · CD20-directed Cytolytic Antibody

Ocrelizumab

OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
  • Primary progressive MS, in adults
  • Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more.
Do not take if
  • Active HBV infection
  • A history of life-threatening infusion reaction to OCREVUS

What it is used for

OCREVUS is indicated for the treatment of:

  • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
  • Primary progressive MS, in adults
  • Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more.

Side effects, and when to stop

The following serious adverse reactions are discussed elsewhere in the labeling:

Who should not take it

OCREVUS is contraindicated in patients with:

  • Active HBV infection
  • A history of life-threatening infusion reaction to OCREVUS

Storing it

Store OCREVUS vials at 2°C to 8°C (36°F to 46°F) in the outer carton to protect from light. Do not freeze or shake.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Ocrelizumab; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/ocrelizumab

APA 7th

sofidex. (2026, August 3). Ocrelizumab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/ocrelizumab

AMA 11th

Ocrelizumab. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/ocrelizumab

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.